NASDAQ · ADPT
Adaptive Biotechnologies Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ADPT: Nov 04, 2026
Adaptive Biotechnologies Corporation Common Stock is expected to report earnings on 11/04/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.1. The reported EPS for the same quarter last year was $-0.15.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.10 | $-0.10 | $-0.10 | 3 |
| Dec 2026 | $-0.06 | $-0.05 | $-0.08 | 3 |
| Mar 2027 | $-0.09 | $-0.07 | $-0.11 | 3 |
| Jun 2027 | $-0.05 | $-0.04 | $-0.06 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · MarketBeat- Fintel · Oct 2, 1:43 AM EDTAdaptive Biotechnologies Consensus Price Target Increased by 11.11% to $28.05The average one-year price target for Adaptive Biotechnologies (NASDAQGS:ADPT) (MUN:1HM) has been revised to $28.05 / share. This is an increase of 11.11% from the prior estimate of $25.24 dated September 11, 2026. These figures represent an aggregate of analyst targets and do no
- RTTNews · Sep 25, 8:30 AM EDTAdaptive Biotechnologies Spotlights MRD Testing In Myeloma Cure Criteria(RTTNews) – Adaptive Biotechnologies Corp. (ADPT), a commercial-stage biotechnology company focused on immune system diagnostics and therapeutics, highlighted a new consensus definition of cure for multiple myeloma presented at the International Myeloma Society (IMS) 23rd Annual
- RTTNews · Sep 25, 4:39 AM EDTBiotech Stocks At 52-Week Highs – CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY(RTTNews) – The following biotech stocks reached a 52-week high on September 24, 2026, driven by key catalysts such as reaching certain regulatory milestones or results from clinical trials.
- RTTNews · Sep 17, 4:10 AM EDTBiotech Stocks At 52-Week Highs – BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOG(RTTNews) – The following biotech stocks reached a 52-week high on September 16, 2026, driven by positive results from clinical trials or an upcoming conference participation.
- RTTNews · Aug 2, 6:54 AM EDT5 Biotech Stocks That Delivered Big Gains – Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX(RTTNews) – As Warren Buffett once said, "If you find three wonderful businesses in your life, you'll get very rich." His message underscores the importance of identifying a handful of exceptional companies capable of delivering sustained long-term value, rather than chasing nume
- Zacks · Jul 31, 9:15 AM EDTAdaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- RTTNews · Jul 30, 3:10 AM EDTAdaptive Biotechnologies Q2 Net Loss Widens Despite Revenue Growth; Stock Down(RTTNews) – Adaptive Biotechnologies Corp. (ADPT), a commercial-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, reflecting a wider net loss amid revenue growth. In addition, the company also provided an update on its full-year 2
- Zacks · Jul 29, 7:00 PM EDTAdaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to SayWhile the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Zacks · Jul 29, 6:25 PM EDTAdaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue EstimatesAdaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Jul 29, 6:03 PM EDTAdaptive Biotechnologies Q2 Earnings Call HighlightsAdaptive Biotechnologies (NASDAQ:ADPT) reported second-quarter results marked by accelerating growth in its minimal residual disease, or MRD, business, improved margins and an increased full-year revenue outlook. The company also outlined further steps toward separating its Immun
- Zacks · Jul 23, 10:00 AM EDTAgios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseAgios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Jul 22, 10:00 AM EDTAdaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseAdaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Adaptive Biotechnologies Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.